phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
Published 1 year ago • 88 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
1:01
phase i study of ruxolitinib plus abemaciclib for patients with myelofibrosis
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
2:15
a phase i study investigating ruxolitinib and abemaciclib for primary or secondary myelofibrosis
-
3:44
phase ii study update of navtemadlin in patients with myelofibrosis r/r to ruxolitinib
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
5:12
ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
2:00
the role of fedratinib in 2024 and beyond
-
14:40
primary myelofibrosis (pmf)
-
20:01
primary myelofibrosis - overview (presentation, pathophysiology, investigation, treatment)
-
4:10
the management of prefibrotic myelofibrosis
-
2:39
a phase ii trial of ruxolitinib and azacitidine combination therapy in patients with myelofibrosis
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
2:12
refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
-
2:36
phase ii study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:52
results of phase i study of mcl-1 inhibition with azd5991 in r/r hematologic malignancies
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct